HERTHENA-Lung02: Phase III trial of patritumab deruxtecan in EGFR-mutated NSCLC post EGFR TKI

Поділитися
Вставка
  • Опубліковано 27 вер 2024
  • This video article presents the phase III HERTHENA-Lung02 study protocol, investigating the use of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
    Subscribe: / @videojournalofbiomedi...
    Visit The Video Journal of Biomedicine: www.biomedicin...
    Follow us on X: / vjofbiomedicine
    LinkedIn: / video-journal-of-biome...
    Facebook: / videojournalbiomedicine
    #cancer #egfr #nsclc #lungcancer

КОМЕНТАРІ •